ACADIA Pharmaceuticals Inc. P/E Ratio 2009–2025
ACADIA Pharmaceuticals Inc. reported 11.61 of price-to-earnings ratio for fiscal 2025. That was 13.9% lower than fiscal 2024. Compared with fiscal 2010, the change was +277.4%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 11.61 | -13.9% |
| FY 2024 | 13.49 | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | 3.08 | — |
| FY 2009 | — | — |
Source: ACADIA Pharmaceuticals Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ACAD 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
ACADIA Pharmaceuticals Inc. reported 11.61 of price-to-earnings ratio for fiscal 2025. That was 13.9% lower than fiscal 2024. Compared with fiscal 2010, the change was +277.4%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for ACADIA Pharmaceuticals Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeACADIA Pharmaceuticals Inc. — frequently asked questions
What is ACADIA Pharmaceuticals Inc.'s price-to-earnings ratio?
ACADIA Pharmaceuticals Inc. (ACAD) reported price-to-earnings ratio of 11.61 for fiscal year 2025, per its SEC filings.
How has ACADIA Pharmaceuticals Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, ACAD's price-to-earnings ratio grew at roughly 8.7% per year (compound annual rate), from 3.08 to 11.61.
Where does this data come from?
Figures are computed from ACADIA Pharmaceuticals Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More ACAD financial history
Full ACAD fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →